Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma
Abstract Several studies have highlighted that Mago-nashi homolog (MAGOH) contributed greatly to cell development, growth, and malignant progression in multiple cancer types. Nevertheless, the role of MAGOH in pan-cancer datasets, particularly in hepatocellular carcinoma (HCC), remains uninvestigate...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-08678-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238771254427648 |
|---|---|
| author | Zezhi Qiu Yi Le Yanyu Liao Xiao Chen Xing Xin Fengting Nie Xianpin Wei Heng Wang Ziling Fang |
| author_facet | Zezhi Qiu Yi Le Yanyu Liao Xiao Chen Xing Xin Fengting Nie Xianpin Wei Heng Wang Ziling Fang |
| author_sort | Zezhi Qiu |
| collection | DOAJ |
| description | Abstract Several studies have highlighted that Mago-nashi homolog (MAGOH) contributed greatly to cell development, growth, and malignant progression in multiple cancer types. Nevertheless, the role of MAGOH in pan-cancer datasets, particularly in hepatocellular carcinoma (HCC), remains uninvestigated. In this study, we first utilized diverse databases to systematically analyze the expression and significance of MAGOH across pan-cancer. Besides, we validated the clinical significance and biological functions of MAGOH in HCC via clinical specimens and in vitro experiments. Bioinformatic analysis has demonstrated that MAGOH was frequently overexpressed in multiple tumors compared to adjacent non-cancerous tissues. Moreover, high expression of MAGOH was related to poorer overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) in certain malignancies, notably an independent prognostic predictor for liver hepatocellular carcinoma (LIHC). Furthermore, MAGOH was closely correlated with immune cell infiltration, immune checkpoint expression, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) status. Subsequently, we found that the expression of MAGOH was largely increased in clinical HCC tissues (34/60, 56.7%) compared to non-cancerous tissues. Additionally, MAGOH was positively correlated with advanced TNM staging and vascular invasion. More convincingly, MAGOH upregulation facilitated cell proliferation, migration, and invasion of HCC cells, while MAGOH depletion elicited opposite effects. Collectively, our study conducted a comprehensive analysis of the hitherto undescribed role of MAGOH in pan-cancer by analyzing multi-omics data. More significantly, we recognized MAGOH as a crucial promoter in the malignant progression of hepatocellular carcinoma, providing potential therapeutic targets for HCC patients. |
| format | Article |
| id | doaj-art-6f5b29d5ad484897b8be638e89200917 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-6f5b29d5ad484897b8be638e892009172025-08-20T04:01:25ZengNature PortfolioScientific Reports2045-23222025-07-0115111710.1038/s41598-025-08678-9Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinomaZezhi Qiu0Yi Le1Yanyu Liao2Xiao Chen3Xing Xin4Fengting Nie5Xianpin Wei6Heng Wang7Ziling Fang8Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Orthopedic, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityAbstract Several studies have highlighted that Mago-nashi homolog (MAGOH) contributed greatly to cell development, growth, and malignant progression in multiple cancer types. Nevertheless, the role of MAGOH in pan-cancer datasets, particularly in hepatocellular carcinoma (HCC), remains uninvestigated. In this study, we first utilized diverse databases to systematically analyze the expression and significance of MAGOH across pan-cancer. Besides, we validated the clinical significance and biological functions of MAGOH in HCC via clinical specimens and in vitro experiments. Bioinformatic analysis has demonstrated that MAGOH was frequently overexpressed in multiple tumors compared to adjacent non-cancerous tissues. Moreover, high expression of MAGOH was related to poorer overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) in certain malignancies, notably an independent prognostic predictor for liver hepatocellular carcinoma (LIHC). Furthermore, MAGOH was closely correlated with immune cell infiltration, immune checkpoint expression, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) status. Subsequently, we found that the expression of MAGOH was largely increased in clinical HCC tissues (34/60, 56.7%) compared to non-cancerous tissues. Additionally, MAGOH was positively correlated with advanced TNM staging and vascular invasion. More convincingly, MAGOH upregulation facilitated cell proliferation, migration, and invasion of HCC cells, while MAGOH depletion elicited opposite effects. Collectively, our study conducted a comprehensive analysis of the hitherto undescribed role of MAGOH in pan-cancer by analyzing multi-omics data. More significantly, we recognized MAGOH as a crucial promoter in the malignant progression of hepatocellular carcinoma, providing potential therapeutic targets for HCC patients.https://doi.org/10.1038/s41598-025-08678-9MAGOH (Mago-nashi homolog)Pan-cancerHepatocellular carcinomaPrognosisTumor progression |
| spellingShingle | Zezhi Qiu Yi Le Yanyu Liao Xiao Chen Xing Xin Fengting Nie Xianpin Wei Heng Wang Ziling Fang Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma Scientific Reports MAGOH (Mago-nashi homolog) Pan-cancer Hepatocellular carcinoma Prognosis Tumor progression |
| title | Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma |
| title_full | Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma |
| title_fullStr | Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma |
| title_full_unstemmed | Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma |
| title_short | Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma |
| title_sort | pan cancer analysis of oncogenic role of magoh and experiment validation in hepatocellular carcinoma |
| topic | MAGOH (Mago-nashi homolog) Pan-cancer Hepatocellular carcinoma Prognosis Tumor progression |
| url | https://doi.org/10.1038/s41598-025-08678-9 |
| work_keys_str_mv | AT zezhiqiu pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT yile pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT yanyuliao pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT xiaochen pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT xingxin pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT fengtingnie pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT xianpinwei pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT hengwang pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma AT zilingfang pancanceranalysisofoncogenicroleofmagohandexperimentvalidationinhepatocellularcarcinoma |